CAR--话题@MedSci

#CAR-#

459篇内容 | 2248人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781097, encodeId=21491e8109738, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=iPS或颠覆通用CAR-T供体来源的问题, objectType=article, longId=64167, objectId=ec706416e13, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec706416e13, replyNumber=0, likeNumber=71, createdTime=2017-01-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec706416e13, moduleTitle=iPS或颠覆通用CAR-T供体来源的问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec706416e13)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781122, encodeId=64a21e811222e, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=大牛Nature全新综述：为免疫疗法“挑大梁”，4大方向让CAR-T更“聪明”！, objectType=article, longId=76605, objectId=7dbde660547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dbde660547, replyNumber=0, likeNumber=68, createdTime=2017-02-06, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dbde660547, moduleTitle=大牛Nature全新综述：为免疫疗法“挑大梁”，4大方向让CAR-T更“聪明”！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dbde660547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781102, encodeId=f8f31e8110273, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=更火爆CAR-T临床国内上马33个，会重蹈替尼覆辙吗？, objectType=article, longId=66526, objectId=cda5665263b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cda5665263b, replyNumber=0, likeNumber=55, createdTime=2016-12-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cda5665263b, moduleTitle=更火爆CAR-T临床国内上马33个，会重蹈替尼覆辙吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cda5665263b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781105, encodeId=2a1d1e81105a4, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=癌症免疫细胞治疗知识：CAR-T与TCR-T的区别在哪里？, objectType=article, longId=67381, objectId=24f76e3810f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24f76e3810f, replyNumber=0, likeNumber=76, createdTime=2016-09-18, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24f76e3810f, moduleTitle=癌症免疫细胞治疗知识：CAR-T与TCR-T的区别在哪里？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24f76e3810f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781107, encodeId=5cd71e8110718, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=内免疫疗法的信心！我国生物技术公司ICT CAR-T治疗B淋巴细胞白血病治愈率达90%, objectType=article, longId=67957, objectId=792e6e95716, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=792e6e95716, replyNumber=0, likeNumber=70, createdTime=2016-08-09, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=792e6e95716, moduleTitle=内免疫疗法的信心！我国生物技术公司ICT CAR-T治疗B淋巴细胞白血病治愈率达90%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=792e6e95716)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781121, encodeId=43b91e8112142, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T进入慢车道, objectType=article, longId=76499, objectId=b63ae64998a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b63ae64998a, replyNumber=0, likeNumber=93, createdTime=2017-03-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b63ae64998a, moduleTitle=CAR-T进入慢车道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b63ae64998a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781114, encodeId=6d821e81114aa, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=杨林教授：CAR-T细胞技术在实体肿瘤应用上的挑战及CAR-NK技术的崛起, objectType=article, longId=71585, objectId=22e1e1585bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22e1e1585bd, replyNumber=0, likeNumber=47, createdTime=2016-10-27, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22e1e1585bd, moduleTitle=杨林教授：CAR-T细胞技术在实体肿瘤应用上的挑战及CAR-NK技术的崛起, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22e1e1585bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781101, encodeId=d21b1e8110139, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=全国首例人源化CD19 CAR-T细胞治疗白血病在徐医附院获得成功！, objectType=article, longId=66492, objectId=d17466492d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d17466492d5, replyNumber=0, likeNumber=66, createdTime=2017-01-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d17466492d5, moduleTitle=全国首例人源化CD19 CAR-T细胞治疗白血病在徐医附院获得成功！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d17466492d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781116, encodeId=37191e81116e1, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=FDA许可Juno继续进行CAR-T细胞治疗临床试验，化疗药物更换为环磷酰胺（ROCKET试验）, objectType=article, longId=72726, objectId=3fcee272613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fcee272613, replyNumber=0, likeNumber=81, createdTime=2017-01-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fcee272613, moduleTitle=FDA许可Juno继续进行CAR-T细胞治疗临床试验，化疗药物更换为环磷酰胺（ROCKET试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fcee272613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781109, encodeId=dd611e81109f5, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=张同存教授：血液病中CAR-T的治疗研究, objectType=article, longId=68335, objectId=c7c66833538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7c66833538, replyNumber=0, likeNumber=67, createdTime=2016-06-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7c66833538, moduleTitle=张同存教授：血液病中CAR-T的治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7c66833538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781094, encodeId=1d9a1e8109478, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T在癌症免疫细胞治疗：现在与明天, objectType=article, longId=60609, objectId=2e1a6060939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e1a6060939, replyNumber=0, likeNumber=70, createdTime=2016-05-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e1a6060939, moduleTitle=CAR-T在癌症免疫细胞治疗：现在与明天, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e1a6060939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781088, encodeId=51b11e81088aa, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T疗法发明者Carl H. June演讲：决胜癌症的CAR-T治疗, objectType=article, longId=56664, objectId=1d1256664f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d1256664f7, replyNumber=0, likeNumber=85, createdTime=2015-12-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d1256664f7, moduleTitle=CAR-T疗法发明者Carl H. June演讲：决胜癌症的CAR-T治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d1256664f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781095, encodeId=f7e21e810952e, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=全球CAR-T疗法研发格局大观 (方正证券), objectType=article, longId=60977, objectId=b048609e74c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b048609e74c, replyNumber=0, likeNumber=84, createdTime=2016-10-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b048609e74c, moduleTitle=全球CAR-T疗法研发格局大观 (方正证券), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b048609e74c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781091, encodeId=a2d01e81091ca, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=上海仁济医院CAR-T细胞治疗脑胶质瘤，肿瘤缩小超过50%, objectType=article, longId=58550, objectId=b1a058550af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1a058550af, replyNumber=0, likeNumber=81, createdTime=2016-08-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1a058550af, moduleTitle=上海仁济医院CAR-T细胞治疗脑胶质瘤，肿瘤缩小超过50%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1a058550af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781086, encodeId=efb21e810867d, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Sci Transl Med：CAR-T对难治或复发性慢性淋巴细胞白血病疗效显著, objectType=article, longId=56369, objectId=958e5636923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=958e5636923, replyNumber=0, likeNumber=71, createdTime=2015-11-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=958e5636923, moduleTitle=Sci Transl Med：CAR-T对难治或复发性慢性淋巴细胞白血病疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=958e5636923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781096, encodeId=2c4d1e810969f, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=【盘点】CAR-T细胞疗法进展一览, objectType=article, longId=64052, objectId=9c9364052d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c9364052d6, replyNumber=0, likeNumber=101, createdTime=2016-05-14, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c9364052d6, moduleTitle=【盘点】CAR-T细胞疗法进展一览, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c9364052d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781093, encodeId=cd7a1e81093f6, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=震撼：CAR-T细胞疗法CTL019在2期r/r ALL临床试验中获得93%的完全应答率, objectType=article, longId=60483, objectId=3e7a604835d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e7a604835d, replyNumber=0, likeNumber=79, createdTime=2016-04-05, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e7a604835d, moduleTitle=震撼：CAR-T细胞疗法CTL019在2期r/r ALL临床试验中获得93%的完全应答率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e7a604835d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781085, encodeId=f5951e81085c5, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T市场风云再起：基因编辑公司Cellectis携手MD Anderson, objectType=article, longId=55887, objectId=4d995588e8e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d995588e8e, replyNumber=0, likeNumber=70, createdTime=2015-11-05, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d995588e8e, moduleTitle=CAR-T市场风云再起：基因编辑公司Cellectis携手MD Anderson, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d995588e8e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781108, encodeId=9e8f1e8110880, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=两项CAR-T技术卖了5800万, objectType=article, longId=68203, objectId=84c468203d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84c468203d1, replyNumber=0, likeNumber=72, createdTime=2016-05-22, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84c468203d1, moduleTitle=两项CAR-T技术卖了5800万, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84c468203d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781084, encodeId=061c1e81084b5, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=J Immunol：CAR-T和TCR-T的前景与挑战, objectType=article, longId=55610, objectId=a6b655610ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6b655610ca, replyNumber=0, likeNumber=65, createdTime=2016-02-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6b655610ca, moduleTitle=J Immunol：CAR-T和TCR-T的前景与挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6b655610ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

iPS或颠覆通用CAR-T供体来源的问题

2017-01-20

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

大牛Nature全新综述：为免疫疗法“挑大梁”，4大方向让CAR-T更“聪明”！

2017-02-06

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

更火爆CAR-T临床国内上马33个，会重蹈替尼覆辙吗？

2016-12-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

癌症免疫细胞治疗知识：CAR-T与TCR-T的区别在哪里？

2016-09-18

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

内免疫疗法的信心！我国生物技术公司ICT CAR-T治疗B淋巴细胞白血病治愈率达90%

2016-08-09

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T进入慢车道

2017-03-20

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

杨林教授：CAR-T细胞技术在实体肿瘤应用上的挑战及CAR-NK技术的崛起

2016-10-27

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

全国首例人源化CD19 CAR-T细胞治疗白血病在徐医附院获得成功！

2017-01-01

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

FDA许可Juno继续进行CAR-T细胞治疗临床试验，化疗药物更换为环磷酰胺（ROCKET试验）

2017-01-20

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

张同存教授：血液病中CAR-T的治疗研究

2016-06-08

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T在癌症免疫细胞治疗：现在与明天

2016-05-08

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T疗法发明者Carl H. June演讲：决胜癌症的CAR-T治疗

2015-12-23

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

全球CAR-T疗法研发格局大观 (方正证券)

2016-10-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

上海仁济医院CAR-T细胞治疗脑胶质瘤，肿瘤缩小超过50%

2016-08-23

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Sci Transl Med：CAR-T对难治或复发性慢性淋巴细胞白血病疗效显著

2015-11-30

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

【盘点】CAR-T细胞疗法进展一览

2016-05-14

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

震撼：CAR-T细胞疗法CTL019在2期r/r ALL临床试验中获得93%的完全应答率

2016-04-05

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T市场风云再起：基因编辑公司Cellectis携手MD Anderson

2015-11-05

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

两项CAR-T技术卖了5800万

2016-05-22

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

J Immunol：CAR-T和TCR-T的前景与挑战

2016-02-02

科室
- - 订阅+
  - 更多科室
工具
服务